A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Active, not recruiting · Phase 1 · NCT04188548
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
At a glance
- Research payments reported, 2025
- $855,370
- U.S. investigators named
- 21
- Sites paid
- 25
- Planned or actual enrollment
- 379
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3484356 (drug), Abemaciclib (drug), Everolimus (drug), Alpelisib (drug), Trastuzumab (drug), Aromatase Inhibitor (AI) (drug), Pertuzumab (drug)
- Dates
- Started 2019-12-10; completion 2027-12
- Results posted
- Not yet
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $855,370 in research payments for this study in 2025 (33 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Rohit R. Rao, M.D Hematology & Oncology · Jacksonville, FL
- Manali A. Bhave, MD Medical Oncology · Chicago, IL
- Jessica J. Tao, MD Internal Medicine · Baltimore, MD
- Karthik V. Giridhar, MD Medical Oncology · Rochester, MN
- Eric M. Lander, MD Hematology & Oncology · Minneapolis, MN
- Cynthia X. Ma, MD Medical Oncology · Saint Louis, MO
- Peter A. Kaufman, MD Medical Oncology · Lebanon, NH
- Ajay Dhakal, M.B.B.S. Hematology · Rochester, NY
- Komal Jhaveri Medical Oncology · New York, NY
- Nicole O. Williams, M.D. Medical Oncology · Columbus, OH
- Debra L. Richardson, M.D. Gynecologic Oncology · Oklahoma City, OK
- Don S. Dizon, MD Medical Oncology · Providence, RI
- Muralidhar Beeram, M.D. Medical Oncology · San Antonio, TX
- Allyson L. Harroff, M.D. Hematology & Oncology · San Antonio, TX
- Cynthia R. Osborne, MD Medical Oncology · Dallas, TX
- Donald A. Richards, MD Medical Oncology · Tyler, TX
- Nisha Unni, M.D. Hematology & Oncology · Dallas, TX
- Kathleen K. Harnden, M.D. Medical Oncology · Fairfax, VA
- Mark D. Kochenderfer, MD Hematology & Oncology · Roanoke, VA
- Kalyan Banda, M.D Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Inova Loudoun Hospital, VA $322,855
- Univ. of Vermont - Fletcher Allen Health Care, VT $90,296
- University of Washington Medical Ctr, WA $72,534
- Emory University Hospital, GA $59,605
- Mayo Clinic Jacksonville $38,282
- Strong Memorial Hospital, NY $37,043
- The University of Texas $35,413
- Texas Oncology PA $25,992
- Highlands Oncology Group PA $25,276
- Memorial Sloan-Kettering $23,754
- Washington University $22,287
- Rhode Island Hospital, RI $20,546
- South Texas Accelerated Research Therapeutics LLC $18,733
- Johns Hopkins University $15,263
- Minnesota Oncology Hematology PA $14,874
- US Oncology Research LLC $10,320
- Mayo Clinic $9,551
- Sarah Cannon Research Institute LLC $8,390
- State of Oklahoma Board of Regents of the University of Oklahoma $2,517
- Oncology and Hematology Assoc of Sw Virginia Inc $956
- The Ohio State University $421
- Sloan Kettering Inst for Cancer Research $200
- University of Colorado Hospital Authority, CO $106
- Savin Center PA $100
- Pma Medical Specialists LLC $56
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.